To compare healthcare costs and resource utilization for overactive bladder patients who persisted on Mirabegron with those who switched to Onabotulinumtoxina

Trial Profile

To compare healthcare costs and resource utilization for overactive bladder patients who persisted on Mirabegron with those who switched to Onabotulinumtoxina

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top